Abstract 17P
Background
Gastric cancer is a multifaceted condition exhibiting varied responses to treatment, emphasizing the need for tailored therapeutic strategies. This study endeavors to elucidate the cellular interactions and molecular mechanisms that underlie the response to Sintilimab plus SOX (fluorouracil plus oxaliplatin) therapy among gastric cancer patients.
Methods
Single-cell sequencing and multiplex immunohistochemistry (mIHC) were employed to elucidate the spatial characteristics linked to the response of gastric cancer to chemo- and immuno- treatment. By integration of mIHC, feature extraction, and machine learning algorithms, we elucidated the intricate interactions between cellular populations and developed a Support Vector Machine (SVM) model for the prediction of treatment response.
Results
We initially discovered a significant correlation between apical membrane cells and resistance to fluorouracil and oxaliplatin, both crucial components of the treatment regimen. This prompted us to delve into the involvement of apical membrane cells in treatment response. Through a thorough examination of cell interactions, we noted substantial connections between apical membrane cells and resident macrophages. Further analysis of ligand-receptor interactions unveiled specific molecular associations, with TGFB1-HSPB1 and LTF-S100A14 interactions standing out, indicating potential signaling pathways implicated in treatment response. To forecast treatment response, we developed an SVM model integrating six markers (DUOX2, HSPB1, S100A14, C1QA, TGFB1, and LTF), which demonstrated outstanding predictive capacity, achieving high area under the curve (AUC) values of 0.93 in the exploration cohort and 0.84 in the validation cohort.
Conclusions
Our research underscored the importance of integrating multi-omics data alongside spatial information in predictive model, holding the promise of steering personalized therapeutic decisions and enhancing treatment efficacy.
Legal entity responsible for the study
The First Affiliated Hospital, School of Medicine, Zhejiang University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display